Kthrough therapy designation.(43) Other 3G-TKI, nazartinib (EGF816) and ASP8273, are undergoing clinical evaluation.(44)Treatment Strategy by
Kthrough therapy designation.(43) Other 3G-TKI, nazartinib (EGF816) and ASP8273, are undergoing clinical evaluation.(44)Treatment Strategy...